Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Ratio (2016 - 2025)

Lipocine's Equity Ratio history spans 14 years, with the latest figure at 0.88 for Q3 2025.

  • For Q3 2025, Equity Ratio fell 4.74% year-over-year to 0.88; the TTM value through Sep 2025 reached 0.88, down 4.74%, while the annual FY2024 figure was 0.93, 5.33% up from the prior year.
  • Equity Ratio reached 0.88 in Q3 2025 per LPCN's latest filing, down from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.95 in Q3 2022 to a low of 0.76 in Q2 2021.
  • Average Equity Ratio over 5 years is 0.9, with a median of 0.92 recorded in 2025.
  • Peak YoY movement for Equity Ratio: skyrocketed 168.51% in 2021, then dropped 6.7% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.87 in 2021, then grew by 9.32% to 0.95 in 2022, then fell by 6.7% to 0.89 in 2023, then increased by 5.33% to 0.93 in 2024, then dropped by 5.67% to 0.88 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Equity Ratio are 0.88 (Q3 2025), 0.92 (Q2 2025), and 0.94 (Q1 2025).